GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,956 DKK | -0.69% |
|
-2.56% | -9.21% |
| 05:18pm | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
| 05:55am | Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
02/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,970
DKK
Average target price
2,463
DKK
Spread / Average Target
+25.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.21% | 18.31B | |
| -3.24% | 102B | |
| +1.68% | 96.29B | |
| +2.13% | 22.18B | |
| -15.68% | 21.2B | |
| -39.98% | 17.38B | |
| -14.75% | 16.36B | |
| +5.83% | 13.97B | |
| +33.79% | 12.17B | |
| +322.35% | 8.32B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- RBC Boosts Price Target on Genmab to DKK3,300 From DKK3,139, Calls Q3 'Solid,' Maintains Outperform Rating
